Krazati fails confirmatory trial in colorectal cancer, putting approval at risk

April 30, 2026 02:37 PM EDT R&D Bris­tol My­er­s' Kraza­ti fails con­fir­ma­to­ry tri­al in col­orec­tal can­cer, putting ap­proval at risk Max Gelman Senior Editor Bris­tol My­ers Squibb’s can­cer drug Kraza­ti has failed its con­fir­ma­to­ry study in sec­ond-line col­orec­tal can­cer, a com­pa­ny spokesper­son con­firmed to End­points News. Kraza­ti had re­ceived … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER